Browse drugs

…he results of the ongoing SEPRA trial, we found that injectable semaglutide was superior to SoC with 30% more patients achieving A1C <7% at…

…m diagnosis. 21/23 (91%) received antiTNF prior to switching to Vedolizumab. 2/23(8.7%) had received Ustekinumab. 19/23 (82.6%) were on Aza…

…ne. As table 4 showed, we found that replacing OGTT 2-h PG with OGTT 1-h PG under the ADA diagnostic standard still retained good consisten…

…c MGMT-deficient G1/G2 PanNET treated with TMZ, with or without capecitabine, reportedly experienced histological progression to G3 disease …

…L-6 (A) and CRP (B) levels in patients treated with and without sarilumab prophylaxis…

… (VAS score)1.3±1.6—1.0±1.82 (1.3)0.3 (0.0 to 0.7)*0.004Mean±SD paracetamol use in the first 7 days (days)4.2±1.9—3.5±2.42 (1.3)0.7 (0.5 to…

…r chronic pain at 90-day follow-up. TCCC has updated intranasal ketamine dosing recommendations to 100mg, which may be more effective.Ab…

…reatinine-cystatin) and EKFC (EKFCcreatinine, EKFCcystatin, and EKFCcreatinine-cystatin).5 20 24 25 In 2021, CKD-EPI published revisions to the CKD-EPI…

… pure mu agonist opioid drugs, such as morphine, oxycodone, and fentanyl. Treatment is challenging due to the prevalence and complexity …

…y receptor OX40. Here, we investigate a treatment strategy with ABBV-368 combined with the investigational toll-like receptor 9 agonist …

…rimary objective is to determine the safety and tolerability of NP-101. The secondary objective is to assess the preliminary antitumor…

…n TKI-resistant lung cancer bearing humanized mice, compared to αPD-1 or αPD-1/αVEGF bsAbs.Conclusions αPD-1/αVEGF/IL-2v is a highly …